Vascular Dementia Market Expected to Grow at 4.5% Through 2036

The vascular dementia market is anticipated to expand at a moderate CAGR of 4.5% during the forecast period from 2026 to 2036. Increasing disease prevalence, population aging, a growing burden of stroke and cardiovascular risk factors, and improvements in diagnostic technologies are expected to support market expansion. The development of emerging therapies, including Apabetalone by Resverlogix, BAC by Charsire Biotechnology, PNA1 and PNA5 by ProNeurogen, Rifaximin SSD by Bausch Health, and other investigational candidates, is also expected to create new treatment opportunities.

Recently published insights from DelveInsight provide an in-depth assessment of the vascular dementia landscape, covering current treatment practices, epidemiology, emerging therapies, individual therapy market shares, competitive developments, and market forecasts from 2022 to 2036 across the United States, EU4, the United Kingdom, and Japan.

Vascular Dementia Market Overview

The vascular dementia market was valued at approximately USD 1.3 billion across the 7MM in 2025. The United States represented the largest share, contributing nearly 70% of the total market value during the same year. Across the 7MM, approximately 3 million diagnosed prevalent cases of vascular dementia were reported in 2025, reflecting the substantial healthcare burden associated with vascular cognitive impairment.

Several pharmaceutical and biotechnology companies are actively advancing potential treatments. Key players include Resverlogix, Charsire Biotechnology, ProNeurogen, Bausch Health, Hemostemix, SciNeuro Pharmaceuticals, Can-Fite Biopharma, Primary Peptides, Autifony Therapeutics, and Zhittya Genesis Medicine.

Explore the latest vascular dementia market insights and future opportunities. https://www.delveinsight.com/report-store/vascular-dementia-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Factors Supporting Vascular Dementia Market Growth

The increasing prevalence of vascular dementia is closely associated with demographic aging and the rising incidence of cerebrovascular disorders. Longer life expectancy is expanding the population at risk, increasing the need for effective diagnostic and management strategies.

Cardiovascular and metabolic conditions are another important contributor. Hypertension, diabetes, obesity, atrial fibrillation, and stroke can increase vascular damage and cognitive impairment, potentially driving demand for improved therapeutic approaches.

Diagnostic innovation is also influencing the market. Advances in neuroimaging, blood-based biomarkers, and artificial intelligence-assisted diagnostic technologies may enable earlier and more precise identification of vascular cognitive impairment. Earlier diagnosis could encourage timely intervention and improve disease management.

At the same time, research and development activity is accelerating. Companies are investigating therapies designed to address neurovascular dysfunction, inflammation, epigenetic mechanisms, and cardiometabolic pathways, creating a gradually expanding pipeline of potential disease-modifying treatments.

Vascular Dementia Treatment Landscape

At present, there are no pharmacological therapies specifically approved for vascular dementia. Consequently, treatment generally focuses on controlling vascular risk factors, managing symptoms, preserving cognitive abilities, and reducing the likelihood of additional vascular events.

Antihypertensive medications, anticoagulants, antidiabetic therapies, antiplatelet agents, vasodilators, antidepressants, antipsychotics, and other supportive treatments may be incorporated into patient management depending on individual needs.

Cholinesterase inhibitors can sometimes be considered for cognitive symptoms, while antidepressants may be used for depression and associated behavioral manifestations. Antiplatelet medicines such as aspirin can help reduce the risk of recurrent vascular events, while therapies targeting blood pressure and metabolic disorders address underlying risk factors.

Medications commonly associated with Alzheimer's disease, including donepezil, galantamine, rivastigmine, and memantine, are not specifically approved for vascular dementia but may be considered in patients with mixed dementia involving both vascular and Alzheimer's pathology.

Emerging Vascular Dementia Therapies

The pipeline is gradually shifting toward more targeted approaches. Apabetalone from Resverlogix, BAC from Charsire Biotechnology, PNA1 from ProNeurogen, Rifaximin SSD from Bausch Health, PNA5, ACP-01, and SNP318 are among the investigational candidates being evaluated for their potential roles in vascular cognitive impairment and dementia.

Apabetalone is a selective bromodomain and extraterminal protein inhibitor designed to influence gene expression through epigenetic regulation. Its multi-target mechanism could provide a different approach from conventional treatments that focus primarily on individual disease pathways.

BAC is an investigational anti-inflammatory therapy developed from a Multi-Glycan Complex derived from soybean extract. It is being studied for its potential to address neuroinflammation associated with vascular dementia.

PNA1, developed by ProNeurogen, is an investigational native angiotensin-(1-7) peptide that selectively targets the MAS receptor. The therapy is being explored across vascular cognitive impairment and dementia, traumatic brain injury, and chronic bone cancer pain.

Rifaximin Soluble Solid Dispersion is another candidate being evaluated for vascular dementia. Earlier clinical research has indicated a favorable safety and tolerability profile, alongside changes in systemic inflammation and dementia-associated biomarkers. Its potential mechanism involves modulation of gut microbiota, an area attracting increasing interest in neurodegenerative and cognitive disorders.

Request the vascular dementia report for detailed pipeline and competitive insights. https://www.delveinsight.com/sample-request/vascular-dementia-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Vascular Dementia Competitive Landscape